Low-Dose Naltrexone (LDN) and Ovarian Cancer: Latest Research 2026

By Insight Swarm Research Team, Medical Advisor: Nikhil Joshi, MD, FRCPC

Low-Dose Naltrexone (LDN) and Ovarian Cancer: Latest Research 2026

This page summarizes the current state of scientific research on Low-Dose Naltrexone (LDN) in the context of Ovarian Cancer as of 2026. The field evolves rapidly — this is a research summary, not medical advice. Consult your gynecologic oncologist for personalized guidance.

Compound Overview

Low-Dose Naltrexone (LDN) (Opioid Antagonist / Immunomodulator) — Naltrexone FDA-approved at 50mg; LDN (1.5–4.5mg) is off-label

Mechanism of action: Transient opioid receptor blockade → endorphin upregulation; TLR4 antagonism; microglial modulation; anti-inflammatory

Current evidence level: Phase II trials for MS, Crohn's, fibromyalgia; promising but small studies

2026 Research Landscape

Direct research on Low-Dose Naltrexone (LDN) specifically for Ovarian Cancer remains limited as of 2026, though the mechanistic connections continue to be explored in laboratory settings.

Key areas researchers are currently examining include:

  • Mechanistic studies: Understanding precisely how Low-Dose Naltrexone (LDN) affects the biological pathways involved in Ovarian Cancer progression
  • Safety characterization: Defining appropriate doses and monitoring protocols if clinical use is considered
  • Biomarker identification: Finding measurable indicators that could predict which patients might respond
  • Screening studies: Preclinical models are still being used to establish whether clinical investigation is warranted

Where to Find the Most Current Research

To access the latest peer-reviewed publications:

  • PubMed: Search "(Low-Dose Naltrexone (LDN)[tiab]) AND (Ovarian Cancer[tiab])" at pubmed.ncbi.nlm.nih.gov
  • ClinicalTrials.gov: Search for active and completed trials with Low-Dose Naltrexone (LDN) keywords
  • Google Scholar: Sort by date for most recent publications

Research Gaps

The most significant gaps in the Low-Dose Naltrexone (LDN) + Ovarian Cancer research landscape as of 2026 include: lack of large Phase III randomized trials, limited long-term safety data in Ovarian Cancer patients, and absence of biomarker-selected patient populations who might benefit most.

Medical Disclaimer: This page summarizes published research and is not medical advice. Never start, stop, or change any treatment based on information found online. Always consult qualified healthcare professionals before making treatment decisions.

Get a personalized AI-generated research report at insightswarm.ai.

Frequently Asked Questions

What are the most recent studies on Low-Dose Naltrexone (LDN) for Ovarian Cancer?

The most current peer-reviewed studies can be found on PubMed (pubmed.ncbi.nlm.nih.gov). Search for 'Low-Dose Naltrexone (LDN) Ovarian Cancer' filtered to the last 2 years. The current evidence level is: Phase II trials for MS, Crohn's, fibromyalgia; promising but small studies.

Are there any 2025-2026 clinical trials for Low-Dose Naltrexone (LDN) in Ovarian Cancer?

Check ClinicalTrials.gov with 'Low-Dose Naltrexone (LDN)' as intervention and 'Ovarian Cancer' as condition. Filter by 'Recruiting' status for currently enrolling trials. Your gynecologic oncologist can advise whether any trials may be appropriate for your specific situation.

Has the evidence for Low-Dose Naltrexone (LDN) in Ovarian Cancer changed recently?

The field evolves rapidly. The current evidence classification is: Phase II trials for MS, Crohn's, fibromyalgia; promising but small studies. For the most up-to-date summary, Insight Swarm generates personalized research reports that incorporate the latest publications specific to your case.